anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the use of a functional inhibitor of hsgk1or hsgk3 protein or a negative transcription regulator of the hsgk1 or hsgk3 gene in the production of a medicament for the treatment and/or prophylaxis of a cataract, glaucoma or diabetic neuropathy. Another aspect of the invention relates to the use of a single-stranded or double-stranded nucleic acid comprising the hsgk1 sequence according to Acc No. NM 005627 or one of the fragments thereof or comprising the hsgk3 sequence according to Acc. No. AF169035 or one of the fragments thereof in the diagnosis of a predisposition to the formation of a cataract, glaucoma and/or diabetic neuropathy, in addition to a kit for diagnosis of a predisposition to the formation of a cataract, glaucoma and/or diabetic neuropathy, comprising the above-mentioned nucleic acid.  The invention further relates to various screening methods for identifying and characterizing therapeutically effective substances from a plurality of test substances for the treatment and/or prophylaxis of at least one disease selected from cataracts, glaucoma or diabetic neuropathy.
The invention relates to a drug for treating venereal diseases, and especially relates to a wart eliminating powder for treating pointed wart. The wart eliminating powder is composed of 8 to 15 parts by weight of talcum powder and 2 to 6 parts by weight of borax. The powder is prepared from natural traditional Chinese herbals. The preparation is simple and convenient, the source of raw materials is wide, and the cost is low. The application method of the powder is accord with the principle of traditional Chinese medicine theory. The raw materials are added into a container in sequence, stirred, sieved by a 120-mesh sieve, and filled into small bags. The powder is smeared on the affected parts by cotton swabs. A patient uses two bags for each day, one for the morning and the other for the night, and a treatment course lasts for 10 days. The clinical experiment results show that the curative effect is prominent and reliable, the property is mild, no side or toxic effect has been found, the effective rate can reach 95.83%, and the cure rate can reach 100%.
An optical system measures one or more physiological parameters with a wearable device that includes a light emitting diode (LED) source including a driver and a plurality of semiconductor sources that generate an output optical light. One or more lenses deliver a lens output light to tissue of a user. A detection system receives at least a portion of the lens output light reflected from the tissue and generates an output signal having a signal-to-noise ratio. The detection system comprises a plurality of spatially separated detectors and an analog to digital converter. The detection system increases the signal-to-noised ratio by comparing a first signal with the LEDs off to a second signal with the LEDs on. An imaging system including a Bragg reflector is pulsed and has a near infrared wavelength. A beam splitter splits the light into a sample arm and a reference arm to measure time-of-flight.
Zilganersen will be administered by intrathecal bolus (ITB) injection once every 12 weeks through Week 49. The 60-week double-blind treatment period will be followed by the open-label and long-term extension periods, where participants will receive zilganersen by ITB injection from Week 61 to Week 229.
Acute physiological consequences of ultramarathon running are still unknown, particularly in women. Results from our first studies conducted in 2009 have shown that a large part of fatigue induced by a mountain ultramarathon could be attributed to central fatigue. Indeed, during extreme exercises such as 24h running, strength losses of knee extensor muscles have reached -40% and ¾ of this fatigue was explain by a central deficit while peripheral mechanisms explained only ¼. Similar results have been reported after a mountain ultramarathon despite the fact that several downhill have induced number of eccentric contractions. As a consequence, central fatigue must be particularly investigated. For this purpose, transcranial magnetic stimulation (TMS) has been recently validated to measure supraspinal central fatigue and cortical excitability.

We have investigated the biological consequences and neuromuscular fatigue only in male runners. Data from the literature suggest that amplitude and etiology of fatigue after prolonged exercise might be gender-dependant. However, these physiological data and studies that have paired male and female by level of performance on shorter distances seem contradictory with performance comparison between genders so that the relative superiority of women in ultra-endurance is not ascertained. The hypothesis of a greater fatigue resistance after ultramarathons in women should then be tested. The biological consequences of ultramarathon are far to be negligible in terms of inflammatory syndrome but complete characterization of this syndrome after such an extreme exercise has yet to be done. Also, several cases of renal failure have been reported after ultramarathons. Evaluation of ultramarathon consequences on kidneys is necessary to prevent serious complications. Finally, consequences of an ultramarathon are not only linked to races but also to training, i.e. the prolonged time spent in running to prepare for the races. Energy expenditure can be more than twice the normal one and repeated impact may potentially alter bone metabolism but to the best of our knowledge, there is no study that have assessed the effects of ultra-endurance running on bone tissue, particularly in males.

The main purpose of the present project is thus to quantify supraspinal central fatigue and associated changes in cortical excitability after an extreme exercise such as a mountain ultramarathon: the Ultra-Trail du Mont-blanc, by using TMS. The secondary purpose are (i) to compare neuromuscular and biological alterations induced by a mountain ultramarathon between males and females matched by age and level of performance, (ii) to evaluate, by biological urine and blood samples, the consequences of a mountain ultramarathon on kidneys and (iii) to investigate the hormonal status and bone mineral density of a group of male and female runners who take part to this type of event regularly.
The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
PURPOSE:To obtain a solubilized silk peptide which has excellent miscibility, tyrosinase active-inhibiting action and moisture retention action and is useful as skin cosmetics, by a method wherein a silk fiber is dissolved in a copper-ethylenediamine soln. and the soln. is subjected to a specified treatment. CONSTITUTION:A soln. (A) of a silk fiber dissolved in a copper-ethylenediamine soln. is neutralized, dialyzed for 1-3 days and nights, and filtered by means of suction to obtain a filtrate. To this filtrate is added a strongly acidic cation exchange resin. The mixture is stirred and filtered by means of suction to obtain a filtrate. The filtrate is adjusted with 10N NaOH so as to give 0.1-0.2N NaOH liquid, and heat-treated at 80-90 deg.C for 5-30min. The pH is reverted with dilute sulfuric acid or succinic anhydride to a neutral pH. The filtrate is filtered by means of suction to obtain a solubulized silk peptide having a molecular weight distribution peak at 1,500-5,000. Alternatively, the soln. A is treated at 40-80 deg.C for 1-4hr, neutralized, dialyzed, and then treated with said resin. Then the pH is adjusted with 2N NaOH to 6.0-7.0, to obtain a peptide having a molecular weight distribution peak at 5,000-50,000.
After being informed about the study and potential risks, all patients giving written informed consent will be screened to determine eligibility for study entry. Participants who meet the eligibility requirements will be sent a study device to use in their home environment. Prior to beginning treatment with the device, participants will fill out a quality of life questionnaire. Participants will use the device twice per week, once for treatment on the front side and once for treatment on the back side of the body. Participants will use the device twice a week for 16 weeks, for a total of 32 treatments. After the 16 week treatment duration, participants will fill out a final quality of life questionnaire and a device usability questionnaire.
The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
The invention belongs to the biopharmaceutical. It involves the role and mechanism of PCSK9 in inflammatory immune diseases, and the application of PCSK9 inhibitors to the preparation of drugs for the treatment of inflammatory immune diseases mediated by T cells. In particular, it involves the use of PCSK9 monoclonal antibody, PCSK9 interference RNA and PCSK9 small molecule inhibitors for treating psoriasis, atopic dermatitis, or urticaria. The invention uses psoriasis as an embodiment for the study of inflammatory and immune diseases. It is found that PCSK9 plays an important role in the treatment of inflammatory immune diseases. The PCSK9 monoclonal antibody, PCSK9 interference RNA, and PCSK9 small molecule inhibitor can be further developed for treating inflammatory immune-diseases, such as psoriasis with fewer adverse reactions, at low cost, and with good efficacy.
The immune response to stress diverges with age, with neonatal macrophages implicated in tissue regeneration versus tissue scarring and maladaptive inflammation in adults. Integral to the macrophage stress response is the recognition of hypoxia and pathogen-associated molecular patterns (PAMPs), which are often coupled. The age-specific, cell-intrinsic nature of this stress response remains vague. To uncover age-defined divergences in macrophage crosstalk potential after exposure to hypoxia and PAMPs, we interrogated the secreted proteomes of neonatal versus adult macrophages via non-biased mass spectrometry. Through this approach, we newly identified age-specific signatures in the secretomes of neonatal versus adult macrophages in response to hypoxia and the prototypical PAMP, lipopolysaccharide (LPS). Neonatal macrophages secreted proteins most consistent with an anti-inflammatory, regenerative phenotype protective against apoptosis and oxidative stress, dependent on hypoxia inducible transcription factor-1α (HIF-1α). In contrast, adult macrophages secreted proteins consistent with a pro-inflammatory, glycolytic phenotypic signature consistent with pathogen killing. Taken together, these data uncover fundamental age and HIF-1α dependent macrophage responses that may be targeted to calibrate the innate immune response during stress and inflammation.
Advances in chromatin mapping have exposed the complex chromatin hierarchical organization in mammals, including topologically associating domains (TADs) and their substructures, yet the functional implications of this hierarchy in gene regulation and disease progression are not fully elucidated. Our study delves into the phenomenon of shared TAD boundaries, which are pivotal in maintaining the hierarchical chromatin structure and regulating gene activity. By integrating high-resolution Hi-C data, chromatin accessibility, and DNA double-strand breaks (DSBs) data from various cell lines, we systematically explore the complex regulatory landscape at high-level TAD boundaries. Our findings indicate that these boundaries are not only key architectural elements but also vibrant hubs, enriched with functionally crucial genes and complex transcription factor binding site-clustered regions. Moreover, they exhibit a pronounced enrichment of DSBs, suggesting a nuanced interplay between transcriptional regulation and genomic stability. Our research provides novel insights into the intricate relationship between the 3D genome structure, gene regulation, and DNA repair mechanisms, highlighting the role of shared TAD boundaries in maintaining genomic integrity and resilience against perturbations. The implications of our findings extend to understanding the complexities of genomic diseases and open new avenues for therapeutic interventions targeting the structural and functional integrity of TAD boundaries.
Stressful processes that pediatric oncology patients may be exposed to in the hospital can have a negative effect on the child's anxiety, decrease in activities, and consequently recovery and participation in hospital care. These processes are very difficult for school children as well as for all children. Hospitalization becomes a limiting factor for the school-age child in this period when he is open to mental and physical development, and he starts to attach more importance to socialization and independence. In addition, problems such as painful diagnosis and treatment procedures, side effects of chemotherapy drugs, and insufficient activity support in the hospital may cause the child to stay away from activities. For these reasons, pediatric oncology patients spend their time in their rooms during chemotherapy treatments. With non-pharmacological approaches that can be applied to pediatric oncology patients, chemotherapy-induced symptoms such as fatigue, pain, anxiety and nausea can be reduced, as well as helping to spend the time in the hospital more enjoyable and active. In the studies conducted, it is stated that these approaches are mostly distracting methods. In this context, the use of distraction methods in nursing care is a valuable aspect of care. In our country, randomized controlled studies in which nurses use non-pharmacological methods are quite limited. With the increase of these studies, the use of effective non-pharmacological methods for pediatric oncology patients will be widespread. This study was planned to examine the effect of occupation-based nursing program (OBaNup) in pediatric oncology patients in reducing the symptoms of chemotherapy and on child satisfaction. In the experimental part of the study; It is planned to conduct a randomized controlled single blind experimental study with 60 pediatric oncology patients, including 30 interventions and 30 controls, who received chemotherapy treatment. It is planned to apply OBaNup to the initiative group for an average of 30 minutes a day for five days. Since there is no routine occupation-based nursing program applied to children in the clinic, it is thought that this study can contribute to both the literature and nursing practices. Therefore, in the planned study; It is predicted that OBaNup applied to pediatric oncology patients can reduce the symptoms of chemotherapy and increase satisfaction.
Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
A medical notification apparatus and method for use with a preexisting healthcare facility nurse call system are disclosed. The apparatus sends a message signal to the healthcare facility call system when the apparatus receives and identifies an acoustic signal indicative of a medical device alarm or other parameter. The apparatus comprises an acoustic sensor, a signal processing unit, and an interface unit. A band pass filter, timing gate, and a processor are configured in one embodiment to process the received acoustic signal to identify an acoustic alarm. A memory device may be used to store a set of identification criteria for identifying a variety of acoustic alarms, and to store a set of message signals. The sent message signal is selected from among the stored set of message signals.
PURPOSE: A rapidly disintegrating tablet composition in oral cavity containing montelukast is provided to disintegrate in a short time without foreign feeling and to easily administer without water or beverage. CONSTITUTION: A rapidly disintegrating tablet composition in oral cavity contains montelukast as a pharmacologically active ingredient or pharmaceutically acceptable salt. The active ingredient is contained in 1-30 weight%. The composition additionally contains 20-90 weight% of excipient. The excipient is mannitol having a particle size of 50-500 micron. The composition also contains sweetener, lubricating agent, acidizing and alkalizing agents, foaming agent, aromatic agent, coloring agent, or stabilizer.
Routine procedures in the clinic were performed on the first course (day 0) when the patients came to receive adjuvant chemotherapy and every 21 days thereafter, and oral cryotherapy was not applied to the patients. Before applying the first adjuvant chemotherapy, Nausea Vomiting Training and Guide was given to have equal conditions with the patients in the intervention groups.
and pharmaceutically acceptable salts thereof, where Q, R, R? and R? have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLSI mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLSI kinase mediated disease, including cancer, using such compounds and salts.  Figure 3.
Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
Epidemic models of susceptibles, exposed, infected, recovered and deceased (SΕIRD) presume homogeneity, constant rates and fixed, bilinear structure. They produce short-range, single-peak responses, hardly attained under restrictive measures. Tuned via uncertain I,R,D data, they cannot faithfully represent long-range evolution. A robust epidemic model is presented that relates infected with the entry rate to health care units (HCUs) via population averages. Model uncertainty is circumvented by not presuming any specific model structure, or constant rates. The model is tuned via data of low uncertainty, by direct monitoring: (a) of entries to HCUs (accurately known, in contrast to delayed and non-reliable I,R,D data) and (b) of scaled model parameters, representing population averages. The model encompasses random propagation of infections, delayed, randomly distributed entries to HCUs and varying exodus of non-hospitalized, as disease severity subdues. It closely follows multi-pattern growth of epidemics with possible recurrency, viral strains and mutations, varying environmental conditions, immunity levels, control measures and efficacy thereof, including vaccination. The results enable real-time identification of infected and infection rate. They allow design of resilient, cost-effective policy in real time, targeting directly the key variable to be controlled (entries to HCUs) below current HCU capacity. As demonstrated in ex post case studies, the policy can lead to lower overall cost of epidemics, by balancing the trade-off between the social cost of infected and the economic contraction associated with social distancing and mobility restriction measures.
Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
A high throughput toxicology screening method is provided. In the subject method, at least 10 different compound compositions are tested simultaneously. Each compound composition is tested by contacting it with a plurality, e.g. from about 10 to 1000, of non-mammalian multi-cellular organisms and determining the effect of the compound composition on the organisms. The multi-cellular organisms employed in the subject methods are small, have differentiated tissues and organs and have a rapid generation time. The subject high throughput screening methods find use in a variety of applications, and are particularly suited for use in the toxicology screening of libraries of compounds, such as libraries of combinatorially produced compounds.
This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (\<30/30+ kg/m\^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
All multiple myeloma cell lines examined showed constitutively active IκB kinase (IKK), IκBα phosphorylation and constitutively active NF-κB. Curcumin, a chemopreventive agent, suppressed constitutive IκBα phosphorylation through inhibition of IKK activity and downregulated NF-κB. Curcumin also downregulated expression of NF-κB-regulated gene products such as IκBα, Bcl-2, Bcl-x L , cyclin D1 and interleukin-6. Consequently, curcumin suppressed multiple myeloma cell proliferation and arrested cells at the G1/S phase of the cell cycle. Curcumin also induced apoptosis and chemosensitivity to vincristine. Overall, results presented herein provide a molecular basis for the treatment of multiple myeloma patients with this pharmacologically safe agent.
Microbubbles can be injected into the bloodstream of a patient, for example, a cancer patient undergoing a treatment specifically targeting a biological process in a tumor. The injected microbubbles can act as vascular contrast agents, which can be detected in vivo using high-frequency ultrasound imaging. The microbubbles can have a surface chemistry that allows them to bind to molecular targets in the tumor vasculature. After injection, the microbubbles can selectively adhere to endothelia expressing a target receptor. The selective adhesion can be used to quantify the tumor vasculature in vivo. By imaging the adhered microbubbles with ultrasound, an indication of how tumor vasculature is affected by a specific cancer treatment can be obtained. Such techniques can be used in a clinical setting for rapid determination of anti-cancer treatment efficacy for individual patients.